Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/11536630-000000000-00000PMID 21028920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Iron chelation therapy in the management of thalassemia: the Asian perspectives

  2009cited by this paper
• Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in β-thalassemia

  2009cited by this paper
• Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants

  2009cited by this paper
• UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.

  2008cited by this paper
• Hemostatic and thrombotic markers in patients with hemoglobin E/β‐thalassemia disease

  2007cited by this paper
• Iron Mobilization From Transferrin And Non-Transferrin-Bound-Iron by Deferiprone. Implications in the Treatment of Thalassemia, Anemia of Chronic Disease, Cancer and Other Conditions

  2006cited by this paper
• Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia

  2006cited by this paper
• Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.

  2006cited by this paper
• Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.

  2005cited by this paper
• Structure and function of the spleen

  2005cited by this paper
• Changing Patterns of Thalassemia Worldwide

  2005cited by this paper
• Pharmacogenomics of Deferiprone Metabolism.

  2005cited by this paper
• The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.

  2004cited by this paper
• Hemodynamic assessment of splenomegaly in β-thalassemia patients undergoing splenectomy

  2004cited by this paper
• Thalassemia.

  2004cited by this paper
• Comparison of colorimetry and electrothermal atomic absorption spectroscopy for the quantification of non-transferrin bound iron in human sera.

  2004cited by this paper
• Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.

  2003cited by this paper
• Inherited haemoglobin disorders: an increasing global health problem.

  2001cited by this paper
• Non-transferrin-bound iron in alcohol abusers.

  2001cited by this paper
• Membrane‐bound iron contributes to oxidative damage of β‐thalassaemia intermedia erythrocytes

  2001cited by this paper
• Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).

  2000cited by this paper
• Clinical Manifestation of &bgr;-Thalassemia/Hemoglobin E Disease

  2000cited by this paper
• Clinical and hematologic aspects of hemoglobin E β-thalassemia

  2000cited by this paper
• Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in beta-thalassemia intermedia.

  2000cited by this paper
• The importance of non-transferrin bound iron in disorders of iron metabolism.

  2000cited by this paper
• Clinical and hematologic aspects of hemoglobin E beta-thalassemia.

  2000cited by this paper
• The beta-thalassemias.

  1999cited by this paper
• An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major.

  1999cited by this paper
• The β-Thalassemias

  1999cited by this paper
• Non‐transferrin‐bound iron and cellular toxicity

  1999cited by this paper
• Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

  1998cited by this paper
• Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.

  1995cited by this paper
• Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.

  1992cited by this paper
• Iron metabolism in thalassemia intermedia.

  1990cited by this paper
• Pharmacokinetic studies in humans with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one

  1990cited by this paper
• Iron absorption in patients with beta-thalassaemia/haemoglobin E disease and the effect of splenectomy.

  1983cited by this paper
• Serum ferritin levels in thalassemias and the effect of splenectomy.

  1981cited by this paper
• Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance.

  1981cited by this paper
• INCREASED TRANSFERRIN IRON SATURATION IN SPLENECTOMIZED THALASSAEMIC PATIENTS

  1980cited by this paper
• Serum iron in thalassemia and the effect of splenectomy.

  1979cited by this paper
• Urinary iron excretion in thalassaemia after desferrioxamine administration

  1974cited by this paper
• The thalassaemia syndromes

  1965cited by this paper

• UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients.

  2026cites this paper
• Impact of transferrin levels on iron accumulation in transfusion-dependent beta-thalassemia: A genotype-specific analysis

  2025cites this paper
• Deferiprone therapy improves the oxidative status of LDL in patients with β-thalassaemia/HbE

  2025cites this paper
• Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE

  2022cites this paper
• Randomized, Blinded, Placebo‐ and Positive‐Controlled Crossover Study to Determine the Effect of Deferiprone on the QTc Interval in Healthy Subjects

  2018cites this paper
• Intestinal calcium transport and its regulation in thalassemia: interaction between calcium and iron metabolism

  2018cites this paper
• Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes.

  2016cites this paper
• Effects of renal impairment on the pharmacokinetics of orally administered deferiprone

  2016cites this paper
• Successful Splenectomy for Hypersplenism in Wilson’s Disease: A Single Center Experience from China

  2015cites this paper
• Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization

  2015cites this paper
• Tandem measurements of iron and creatinine by cross injection analysis with application to urine from thalassemic patients.

  2015cites this paper
• Population pharmacokinetics of deferiprone in healthy subjects.

  2014cites this paper
• The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients

  2013cites this paper
• Iron-chelation therapy with oral chelators in patients with thalassemia major

  2013cites this paper
• Deferiprone (GPO‐L‐ONE®) monotherapy reduces iron overload in transfusion‐dependent thalassemias: 1‐year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO‐L‐ONE; A001) from Thailand

  2013cites this paper
• Comparison of Pharmacokinetics and Urinary Iron Excretion of Two Single Doses of Deferiprone in β-Thalassemia/Hemoglobin E Patients

  2012cites this paper